Abstract
In the past decade, researchers have defined committed stem or progenitor cells from various tissues, including bone marrow, peripheral blood, brain, liver and reproductive organs, in both adult animals and humans. Recently, endothelial progenitor cells (EPCs) were isolated from peripheral blood mononuclear cells and were shown to be incorporated into foci of neovascularization. This finding that circulating EPCs may home into sites of neovascularization and differentiate into mature endothelial cells in situ is consistent with the concept of vasculogenesis and suggests that vasculogenesis and angiogenesis might constitute complementary mechanisms for postnatal neovascularization. Furthermore, experimental and clinical studies on ischemic cardiovascular diseases suggest a therapeutic potential for EPC transplantation. In this review, we summarize the biological features of EPCs and discuss their therapeutic potential for the treatment of cardiovascular diseases.
Keywords: Angiogenesis, neovascularization, stem cell, transplantation, vasculogenesis
Current Vascular Pharmacology
Title: Therapeutic Potential of Endothelial Progenitor Cells for Cardiovascular Diseases
Volume: 4 Issue: 1
Author(s): Lijing Jia, Masafumi Takahashi, Toru Yoshioka, Hajime Morimoto, Hirohiko Ise and Uichi Ikeda
Affiliation:
Keywords: Angiogenesis, neovascularization, stem cell, transplantation, vasculogenesis
Abstract: In the past decade, researchers have defined committed stem or progenitor cells from various tissues, including bone marrow, peripheral blood, brain, liver and reproductive organs, in both adult animals and humans. Recently, endothelial progenitor cells (EPCs) were isolated from peripheral blood mononuclear cells and were shown to be incorporated into foci of neovascularization. This finding that circulating EPCs may home into sites of neovascularization and differentiate into mature endothelial cells in situ is consistent with the concept of vasculogenesis and suggests that vasculogenesis and angiogenesis might constitute complementary mechanisms for postnatal neovascularization. Furthermore, experimental and clinical studies on ischemic cardiovascular diseases suggest a therapeutic potential for EPC transplantation. In this review, we summarize the biological features of EPCs and discuss their therapeutic potential for the treatment of cardiovascular diseases.
Export Options
About this article
Cite this article as:
Jia Lijing, Takahashi Masafumi, Yoshioka Toru, Morimoto Hajime, Ise Hirohiko and Ikeda Uichi, Therapeutic Potential of Endothelial Progenitor Cells for Cardiovascular Diseases, Current Vascular Pharmacology 2006; 4 (1) . https://dx.doi.org/10.2174/157016106775203063
DOI https://dx.doi.org/10.2174/157016106775203063 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Potential Role of Rho Kinase Inhibitors in Combating Diabetes-Related Complications Including Diabetic Neuropathy-A Review
Current Diabetes Reviews Beta-Blockers use for Hypertension in the Elderly
Cardiovascular & Hematological Agents in Medicinal Chemistry Progression of Renal Dysfunction in Patients with Cardiovascular Disease
Current Cardiology Reviews Functional Variants of the Interleukin-23 Receptor Gene in Non-Gastrointestinal Autoimmune Diseases
Current Medicinal Chemistry Studying the Ethno-Pharmacological Basis of Antiepileptic Activity of Medhya Rasayanas- A Nootropic Package From Ayurveda
Current Traditional Medicine Complex Inheritance for Susceptibility to Sudden Cardiac Death
Current Pharmaceutical Design Neopterin as a Marker for Immune System Activation
Current Drug Metabolism Triple Threat: The Na+/Ca2+ Exchanger in the Pathophysiology of Cardiac Arrhythmia, Ischemia and Heart Failure
Current Drug Targets Renal Nerve Ablation for Hypertensive Patients with Chronic Kidney Disease
Current Vascular Pharmacology 10 Years of SELDI: What Have we Learnt?
Current Proteomics Modulation of Fatty Acids Oxidation in Heart Failure by Selective Pharmacological Inhibition of 3-Ketoacyl Coenzyme-A Thiolase
Current Clinical Pharmacology A Review on Hematopoietic Stem Cell Treatment for Epilepsy
CNS & Neurological Disorders - Drug Targets Inhibition of the Calcineurin-NFAT Signalling Cascade in the Treatment of Heart Failure
Recent Patents on Cardiovascular Drug Discovery Small Heat Shock Proteins and Protein-Misfolding Diseases
Current Pharmaceutical Biotechnology Cardiovascular Effects of Losartan and Its Relevant Clinical Application
Current Medicinal Chemistry Enterovirus D-68 Molecular Virology, Epidemiology, and Treatment: an Update and Way Forward
Infectious Disorders - Drug Targets Pathogenesis of Age-Related Cataract: A Systematic Review of Proteomic Studies
Current Proteomics Ivabradine: A Current Overview
Current Clinical Pharmacology Mesenchymal Stem Cells: A Good Candidate for Restenosis Therapy?
Current Vascular Pharmacology Stem Cell Therapy for the Treatment of Acute Myocardial Infarction and Chronic Ischemic Heart Disease
Current Pharmaceutical Biotechnology